Advancing a collaboration inked in July 2020, gene therapy specialist Lysogene SA said on 12 April that it is taking its option to license worldwide development and commercial rights to a gene therapy candidate discovered at Israel’s Weizmann Institute of Science for neuronopathic Gaucher disease and Parkinson’s disease. The French biotech inked the agreement with Yeda R&D Company, the commercial arm of the Weizmann Institute.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?